Advancing the battle against acute ischemic syndromes

A focus on the GP IIb-IIIa inhibitors

Paul P Dobesh, Keith A. Latham

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Platelet aggregation and thrombus formation, resulting from disruption of a coronary artery plaque, play a critical role in the pathology of acute coronary syndromes. Currently, aspirin and heparin are administered to decrease platelet aggregation. The discovery of the platelet integrin receptor α(IIb)β3, also known as the platelet glycoprotein (GP) IIb-IIIa receptor, is a breakthrough in antiplatelet therapy. The GP IIb-IIIa receptor is responsible for the crucial binding of fibrinogen to platelets, leading to cross-links between platelets and further platelet aggregation. Since the introduction of abciximab, the first GP IIb-IIIa-receptor antagonist, several other nonantibody agents have been studied for use in percutaneous transluminal coronary angioplasty and also in stent placement, treatment of unstable angina, and myocardial infarction.

Original languageEnglish (US)
Pages (from-to)663-685
Number of pages23
JournalPharmacotherapy
Volume18
Issue number4
StatePublished - Jul 1 1998

Fingerprint

Platelet Glycoprotein GPIIb-IIIa Complex
Platelet Aggregation
Blood Platelets
Integrin beta3
Coronary Balloon Angioplasty
Unstable Angina
Acute Coronary Syndrome
Integrins
Fibrinogen
Aspirin
Stents
Heparin
Coronary Vessels
Thrombosis
Myocardial Infarction
Pathology
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Advancing the battle against acute ischemic syndromes : A focus on the GP IIb-IIIa inhibitors. / Dobesh, Paul P; Latham, Keith A.

In: Pharmacotherapy, Vol. 18, No. 4, 01.07.1998, p. 663-685.

Research output: Contribution to journalReview article

@article{a4afdc98019b4375b4f9092d14b25916,
title = "Advancing the battle against acute ischemic syndromes: A focus on the GP IIb-IIIa inhibitors",
abstract = "Platelet aggregation and thrombus formation, resulting from disruption of a coronary artery plaque, play a critical role in the pathology of acute coronary syndromes. Currently, aspirin and heparin are administered to decrease platelet aggregation. The discovery of the platelet integrin receptor α(IIb)β3, also known as the platelet glycoprotein (GP) IIb-IIIa receptor, is a breakthrough in antiplatelet therapy. The GP IIb-IIIa receptor is responsible for the crucial binding of fibrinogen to platelets, leading to cross-links between platelets and further platelet aggregation. Since the introduction of abciximab, the first GP IIb-IIIa-receptor antagonist, several other nonantibody agents have been studied for use in percutaneous transluminal coronary angioplasty and also in stent placement, treatment of unstable angina, and myocardial infarction.",
author = "Dobesh, {Paul P} and Latham, {Keith A.}",
year = "1998",
month = "7",
day = "1",
language = "English (US)",
volume = "18",
pages = "663--685",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Advancing the battle against acute ischemic syndromes

T2 - A focus on the GP IIb-IIIa inhibitors

AU - Dobesh, Paul P

AU - Latham, Keith A.

PY - 1998/7/1

Y1 - 1998/7/1

N2 - Platelet aggregation and thrombus formation, resulting from disruption of a coronary artery plaque, play a critical role in the pathology of acute coronary syndromes. Currently, aspirin and heparin are administered to decrease platelet aggregation. The discovery of the platelet integrin receptor α(IIb)β3, also known as the platelet glycoprotein (GP) IIb-IIIa receptor, is a breakthrough in antiplatelet therapy. The GP IIb-IIIa receptor is responsible for the crucial binding of fibrinogen to platelets, leading to cross-links between platelets and further platelet aggregation. Since the introduction of abciximab, the first GP IIb-IIIa-receptor antagonist, several other nonantibody agents have been studied for use in percutaneous transluminal coronary angioplasty and also in stent placement, treatment of unstable angina, and myocardial infarction.

AB - Platelet aggregation and thrombus formation, resulting from disruption of a coronary artery plaque, play a critical role in the pathology of acute coronary syndromes. Currently, aspirin and heparin are administered to decrease platelet aggregation. The discovery of the platelet integrin receptor α(IIb)β3, also known as the platelet glycoprotein (GP) IIb-IIIa receptor, is a breakthrough in antiplatelet therapy. The GP IIb-IIIa receptor is responsible for the crucial binding of fibrinogen to platelets, leading to cross-links between platelets and further platelet aggregation. Since the introduction of abciximab, the first GP IIb-IIIa-receptor antagonist, several other nonantibody agents have been studied for use in percutaneous transluminal coronary angioplasty and also in stent placement, treatment of unstable angina, and myocardial infarction.

UR - http://www.scopus.com/inward/record.url?scp=0031827114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031827114&partnerID=8YFLogxK

M3 - Review article

VL - 18

SP - 663

EP - 685

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 4

ER -